Molecular markers of breast axillary lymph node metastasis

被引:16
作者
Cavalli, Luciane R. [1 ]
机构
[1] Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, Washington, DC 20007 USA
关键词
array-CGH; breast cancer; CGH; DNA copy number alterations; gene expression; genome-wide methodology; lymph node metastasis; sentinel lymph node; COMPARATIVE GENOMIC HYBRIDIZATION; GENE-EXPRESSION PROFILES; POLYMERASE CHAIN-REACTION; IN-SITU HYBRIDIZATION; POSITIVE SENTINEL NODE; COPY NUMBER ALTERATION; CANCER PATIENTS; SOLID TUMORS; PROGNOSTIC MARKERS; ESTROGEN-RECEPTOR;
D O I
10.1586/ERM.09.30
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
In breast cancer, axillary lymph node status is one of the most important prognostic variables and a crucial component to the staging system. Several clinico-histopathological parameters are considered to be strong predictors of metastasis; however, they fail to accurately classify breast tumors according to their clinical behavior and to predict which patients will have disease recurrence. Methods based on genome-wide microarray analyses have been used to identify molecular markers with respect to the development of axillary lymph node metastasis. Most of these markers can be detected in the primary tumors, which can potentially lead to the ability to identify patients at the time of diagnosis who are at high risk for lymph node metastasis, allowing for early intervention and more suitable adjuvant treatments.
引用
收藏
页码:441 / 454
页数:14
相关论文
共 201 条
[51]   Mechanisms leading to chromosomal instability [J].
Gollin, SM .
SEMINARS IN CANCER BIOLOGY, 2005, 15 (01) :33-42
[52]  
Goyal A, 2008, CURR OPIN ONCOL, V20, P621, DOI [10.1097/CCO.0b013e32831369cb, 10.1097/CCO.0b013e328315ef1d]
[53]   Advances in endocrine therapy of metastatic breast cancer [J].
Gradishar, WJ ;
Morrow, M .
BRITISH JOURNAL OF SURGERY, 2002, 89 (12) :1489-1492
[54]   Pathologic examination of sentinel lymph nodes in breast cancer by a single haematoxylin-eosin slide versus serial sectioning and immunocytokeratin staining: clinical implications [J].
Groen, Reinou S. ;
Oosterhuis, A. Wolter J. ;
Boers, James E. .
BREAST CANCER RESEARCH AND TREATMENT, 2007, 105 (01) :1-5
[55]   A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients [J].
Habel, Laurel A. ;
Shak, Steven ;
Jacobs, Marlena K. ;
Capra, Angela ;
Alexander, Claire ;
Pho, Mylan ;
Baker, Joffre ;
Walker, Michael ;
Watson, Drew ;
Hackett, James ;
T Blick, Noelle ;
Greenberg, Deborah ;
Fehrenbacher, Louis ;
Langholz, Bryan ;
Quesenberry, Charles P. .
BREAST CANCER RESEARCH, 2006, 8 (03)
[56]   The gene expression signature of genomic instability in breast cancer is an independent predictor of clinical outcome [J].
Habermann, Jens K. ;
Doering, Jana ;
Hautaniemi, Sampsa ;
Roblick, Uwe J. ;
Buendgen, Nana K. ;
Nicorici, Daniel ;
Kronenwett, Ulrike ;
Rathnagiriswaran, Shruti ;
Mettu, Rama K. R. ;
Ma, Yan ;
Krueger, Stefan ;
Bruch, Hans-Peter ;
Auer, Gert ;
Guo, Nancy L. ;
Ried, Thomas .
INTERNATIONAL JOURNAL OF CANCER, 2009, 124 (07) :1552-1564
[57]   Genomic alterations identified by array comparative genomic hybridization as prognostic markers in tamoxifen-treated estrogen receptor-positive breast cancer [J].
Han, W ;
Han, MR ;
Kang, JJ ;
Bae, JY ;
Lee, JH ;
Bae, YJ ;
Lee, JE ;
Shin, HJ ;
Hwang, KT ;
Hwang, SE ;
Kim, SW ;
Noh, DY .
BMC CANCER, 2006, 6 (1)
[58]   The hallmarks of cancer [J].
Hanahan, D ;
Weinberg, RA .
CELL, 2000, 100 (01) :57-70
[59]   Prognostic and predictive factors revisited [J].
Hayes, DF .
BREAST, 2005, 14 (06) :493-499
[60]  
Heimann R, 2000, CANCER RES, V60, P298